{"entity":{"id":"nct07386704","kind":"trial","name":"Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of nimotuzumab in pancreatic cancer, run by Peking University First Hospital, now recruiting.","summary":"Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT07386704 by Peking University First Hospital, with a registry enrolment figure of 30 participants, started 2025-12-09 and due to reach its primary completion in 2026-12-09. Interventions recorded: Nimotuzumab combined with chemoradiotherapy. Conditions listed: Pancreatic Cancer Non-resectable. Primary outcome: LCR. Pancreatic eligibility wording from the registry: \"Confirmed by histological or cytological examination as pancreatic adenocarcinoma;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07386704","url":"https://clinicaltrials.gov/study/NCT07386704"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07386704","phase":"2","setting":"A Prospective, Single-arm Study of Nimotuzumab Combined With Radiotherapy and Chemotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer","sponsor":"Peking University First Hospital","participation":[{"nct":"NCT07386704","source":"https://clinicaltrials.gov/study/NCT07386704","fetchedAt":"2026-10-07T16:55:43.582Z","studySha256":"973c8e82d613c229ce17343164e1a77eb69641ecb7217d238c59723914b3b35d","overallStatus":"ENROLLING_BY_INVITATION","lastUpdatePosted":"2026-02-04","leadSponsor":"Peking University First Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-12-09","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07386704/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}